Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Matthew Cavender MD, MPH

Matthew A. Cavender MD, MPH

Assistant Professor of Medicine; Director, Cardiovascular Clinical Trials, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Dr. Matthew A. Cavender, MD, MPH, is an Assistant Professor and Director of Cardiovascular Clinical Trials at the University of North Carolina in Chapel Hill, NC.

He received his medical degree from the University of Alabama School of Medicine and a Master’s of Public Health from the Harvard School of Public Health. He completed an internship and residency in Internal Medicine at Duke University in Durham, North Carolina, clinical fellowship in cardiology at the Cleveland Clinic in Cleveland, Ohio, and a research and interventional cardiology fellowship at Brigham and Women’s Hospital in Boston, Massachusetts.

He is clinically active as an interventional cardiologist and specializes in transcatheter therapies for patients with advanced coronary artery disease, peripheral vascular disease and valvular heart disease. He has extensive experience in clinical research studying the clinical effectiveness of clinical interventions, devices, and pharmacotherapies.  His research efforts are focused on the effectiveness of existing treatment strategies and therapies for patients with cardiovascular disease, the impact of diabetes on cardiovascular events among patients with coronary artery disease, and pharmacologic and interventional strategies to improve outcomes in patients with diabetes and atherosclerosis.

Dr. Cavender is a Fellow of the American College of Cardiology and member of a number of medical societies and organizations, including the American Heart Association Council of Clinical Cardiology, and the Society for Cardiovascular Angiography and Interventions. Dr. Cavender has authored numerous works on pharmacologic and interventional therapies for patients with coronary artery disease, valvular heart disease, diabetes, and myocardial infarction that have been published in peer-reviewed journals including The New England Journal of Medicine, The Lancet, Circulation and The Journal of the American College of Cardiology. He is on the editorial board of Circulation: Cardiovascular Interventions, Clinical Cardiology, and The American Heart Journal.


Dr. Cavender reports research support to his institution for studies in which he is the principle investigator from Amgen, Boehringer-Ingelheim, CSL Behring; consulting fees from Amgen, Bayer, Boehringer-Ingelheim, Medtronic, Merck, Novo-Nordisk.